Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Patients who require gastric endoscopy, including the patient population* excluded from the
phase III controlled clinical study of NPO-11, will receive an intragastric single dose of
NPO-11 20 mL. The efficacy of NPO-11 as a premedication for endoscopy will be evaluated based
on the percentage of patients having no gastric peristalsis at both 2 minutes post-dose and
the end of endoscopy (primary outcome measure).
The safety of NPO-11 will be evaluated based on adverse events and adverse drug reactions
(ADRs) observed between administration and seven days after administration.
Patient population excluded from the phase III controlled clinical study of NPO-11
- Patients with reflux esophagitis
- Patients with active gastric or duodenal ulcers
- Patients who undergo endoscopy under sedation
- Patients who undergo endoscopy with a scope of <9 mm in diameter